Frequently asked questions
Visible answers below. Structured data mirrors this content for search engines.
What is the difference between peptide research and approved treatment?
Research covers lab work, animal models, and clinical trials under published protocols. Approved treatment means a regulator such as the U.S. FDA has reviewed a product for specific labeled uses.
A compound can have interesting papers and still lack an approved label. Retatrutide’s phase 2 obesity data in the New England Journal of Medicine (DOI 10.1056/NEJMoa2301972) is human trial evidence under protocol conditions; it is not an FDA-approved medicine. BPC-157 has extensive rodent literature (for example PubMed 35125818) and only sparse human reports such as small case series (PubMed 34324435).
CT632 explains research; it does not tell you to use a peptide. Decisions belong with licensed clinicians using lawful products.
What do “before and after” peptide claims actually show?
Photos and anecdotes rarely come with blinding, control arms, or published endpoints. They may reflect lighting, diet, concurrent medicines, or unrelated healing timelines.
When someone cites a study, check whether the outcome was measured in humans or animals, whether the product matches the paper’s molecule, and whether the trial registered primary endpoints before unblinding. Our seven-question checklist walks through that filter.
PeptIQ community charts aggregate self-reported check-ins; PeptIQ labels them as non-clinical. They are not substitutes for trials.
How should I track health notes, wearables, and clinician input?
If you and your clinician already monitor a protocol, structured logs beat scattered screenshots. Useful fields include dose dates (as prescribed), side-effect notes, weight or waist trends, sleep and activity from wearables, and lab results your clinician orders.
Wearables measure proxies, not peptide concentrations. Bring trends to appointments instead of treating apps as diagnosticians.
PeptIQ.io focuses on logging, calculators, and education tooling; CT632 focuses on reading primary literature. Neither replaces medical care.
How do CT632 and PeptIQ.io work together?
CT632 (this site) publishes editorial research summaries, FAQs, and citation-first articles at ct632.com. PeptIQ.io is Kris’s peptide tracking and education app with compound profiles, FDA status tools, and optional Premium features including PeptIQ AI inside the app.
Typical flow: read a CT632 article and its PubMed/DOI links, then use PeptIQ to bookmark the compound profile, log what you and your clinician agreed to track, and read longer guides on the PeptIQ blog. CT632 links to public PeptIQ URLs we verify; we do not operate PeptIQ accounts for you.
Why does CT632 keep separating animal studies from human studies?
Most peptide hype imports rodent healing data directly into human wellness marketing. Translation fails often because of species differences, routes, dosing scales, and injury models that do not mirror outpatient use.
TB-500 analytical papers identify a thymosin β4-related fragment in research products (PubMed 22962027) — that is chemistry and anti-doping science, not proof that a purchased vial reproduces regulated thymosin beta-4 trials. Keeping tiers separate prevents accidental equivalence.
Who writes CT632, and is this peer-reviewed?
Articles are authored by Kris Chase as CT632 editorial. Drafting uses AI tools organized around cited primary sources; Kris approves publish. This is not a peer-reviewed journal, and we do not display medical credential badges.
CT632 is published by PeptIQ LLC. See the about page and contact for corrections and disclosures.